
Eli Lilly
US drugmaker behind Kisunla; backed two British biotech rounds in five days in November 2026.
Last refreshed: 14 November 2026 · Appears in 1 active topic
Why is Eli Lilly buying minority stakes in British biotech?
Timeline for Eli Lilly
Joined Oyster's Series A as a new investor
UK Startups and Innovation: Oyster brings Eli Lilly into $60m roundJoined T-Therapeutics' Series B
UK Startups and Innovation: T-Therapeutics raises $133m in Series BBackground
Eli Lilly put money into two British biotech rounds within five days in November 2026, both times as a minority investor behind a specialist lead. It joined T-Therapeutics' $133m Series B on 5 November and Oyster Therapeutics' $60m Series A on 10 November as a new strategic investor.
The Indianapolis drugmaker sells Kisunla, an antibody that clears amyloid, one of the two proteins linked to Alzheimer's disease. Oyster's degrader targets tau, the other, so the stake gives Lilly an early view of the next mechanism without building it in-house.
Buying in at Series A and B gives a drugmaker early sight of clinical data and a seat near later licensing talks, without setting the price.
Which British biotechs has Eli Lilly invested in?
Why did Eli Lilly invest in Oyster Therapeutics?
What does Eli Lilly sell for Alzheimer's?
Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 14 November 2026. Editorial standards.